How to Store Sermorelin: Stability and Handling, Per the Research

This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical or storage question involving a prescription or research compound. Nothing here is an instruction, a protocol, or a handling procedure for any reader.

What the literature on sermorelin stability actually contains

Sermorelin is a synthetic fragment corresponding to the first 29 amino acids of human growth hormone-releasing hormone (GHRH), and most of the modern peer-reviewed work that touches its physical and chemical behaviour sits in analytical chemistry and anti-doping science rather than in formulation science. A 2023 study on in-house standards derived from doping peptides characterised the enzymatic and serum stability and degradation profile of GHRP- and GHRH-related peptides, which is the nearest thing in the verified literature to a direct degradation study on this peptide class (PMID 37688464). Alongside it, several method-development papers describe how GHRHs were recovered, purified and quantified from biological matrices, including an antibody-free, ultrafiltration-based assay that detected growth hormone-releasing hormones in urine at low pg/mL concentrations using nanoLC-HRMS/MS (PMID 35298973).

That distinction matters for anyone reading storage claims online. Very little of what is written about refrigerating, freezing or travelling with sermorelin traces back to a sermorelin stability trial. Most of it is extrapolated from general lyophilized-peptide chemistry. The sections below label every statement as either compound-specific literature or general peptide science, and never presents the second as the first.

Compound-specific evidence versus general lyophilized-peptide science

What has been measured on GHRH-related peptides directly

The 2023 degradation work generated in-house reference standards from doping peptides and reported enzymatic and serum stability data plus degradation profiles for GHRP- and GHRH-related peptides, meaning the degradation pathways described there were observed in enzyme-containing biological media rather than in a sealed vial on a shelf (PMID 37688464). A separate review of PEGylation of growth hormone-releasing hormone (GRF) analogues discussed chemical modification as a strategy for improving the stability and pharmacokinetic behaviour of GRF analogues, which is an acknowledgement that the unmodified peptide backbone is comparatively labile (PMID 14499707).

Detection studies add indirect handling information, because every method paper had to keep the analyte intact long enough to measure it. Researchers described a cationic exchange solid-phase extraction workflow combined with triple quadrupole UHPLC-MS/MS for detection of GHRHs in urine samples (PMID 37806509), a nano liquid chromatography method coupled with quadrupole/orbitrap mass spectrometry for GHRH and its analogs in urine (PMID 41138283), and an immunoaffinity purification approach with LC-HRMS/MS for qualitative identification of growth hormone-releasing hormones in human plasma (PMID 26879649). None of those papers set out to define a refrigerator shelf life for a finished vial; they defined analytical performance.

What is general peptide chemistry rather than a sermorelin finding

The following points are standard peptide and protein formulation chemistry. They are not attributed to any sermorelin study, and they should be read as background principles rather than measured outcomes for this molecule:

• Water is a reactant. In aqueous solution, peptide bonds can hydrolyse, and side chains such as asparagine and glutamine can deamidate; removing water by lyophilisation slows those reactions substantially.
• Lyophilised (freeze-dried) powder is therefore conventionally treated as the more stable physical state, and reconstituted solution as the less stable one.
• Temperature accelerates chemical degradation. Cold-chain storage is conventionally defined as 2–8 °C, and controlled room temperature is conventionally defined as roughly 20–25 °C.
• Light, oxygen, repeated mechanical agitation and adsorption to container surfaces are recognised stress factors for small peptides in dilute solution.
• Degradation is usually invisible. A solution can lose potency long before anything changes that an eye can detect.

Anyone who sees a specific number — a set number of days after reconstitution, a percentage of potency retained at a given temperature — attached to sermorelin should ask which document it came from. In the verified literature reviewed here, those figures are not present; the stability numbers that do exist relate to serum and enzymatic conditions (PMID 37688464).

Refrigeration: lyophilized powder versus reconstituted solution

Sermorelin acetate was previously marketed in the United States as an approved prescription product and was subsequently discontinued by its manufacturer; material described as sermorelin today is typically either compounded or labelled for research use only. Because the original approved-product labelling is no longer the practical reference point for most circulating material, storage claims tend to be inherited from general cold-chain convention rather than from a current, sermorelin-specific stability file.

The practical reading is that the lyophilized-versus-reconstituted distinction is a chemistry argument, not a sermorelin trial result. The one place where the distinction was quantified for this peptide family was in biological media, where the study measured degradation in serum and with enzymes present (PMID 37688464) — conditions that do not correspond to a sealed vial.

Shelf life and expiry dating: how stability is established

Expiry dates on pharmaceutical peptides are generated by formal stability programmes: batches are held at defined temperatures and humidities, sampled at intervals, and assayed for potency and impurity growth. That process is regulatory and proprietary, and its outputs sit in submission dossiers rather than in indexed journals. Consequently, a PubMed search returns detection chemistry for GHRHs — for example the ultrafiltration-based urine assay operating at low pg/mL concentrations (PMID 35298973) — but not a published expiry study for sermorelin vials.

Research-use-only material carries an additional wrinkle: RUO labelling does not require the same stability documentation as an approved drug product, so a printed date on such a vial may reflect a supplier convention rather than a tested endpoint. A 2026 critical review of peptide and peptide-analog drug use in recreational and professional sport and bodybuilding discussed the wider quality and provenance problems surrounding non-pharmaceutical peptide supply (PMID 41880199).

Room temperature and travel conditions

No paper in the verified set tested sermorelin at ambient or elevated temperature over time. What the analytical literature does show is that laboratories handling GHRHs built deliberate sample-preparation controls around the analyte: cationic exchange SPE before triple quadrupole UHPLC-MS/MS detection in urine (PMID 37806509) and immunoaffinity purification before LC-HRMS/MS in plasma (PMID 26879649). Those extraction steps exist because the peptide is present at trace levels and because matrix components can interfere with or consume it.

Travel-related claims — insulated packs, transit windows, cabin versus hold — are logistical conventions rather than published findings for this compound. Where a temperature excursion figure is quoted for sermorelin, the verified literature does not supply it, and this page does not manufacture one.

Freezing and freeze–thaw cycles

Freezing is a general stabilisation tool for peptides in solution, and freeze–thaw cycling is a general stress factor, because ice-front formation concentrates solutes and can drive aggregation or surface denaturation. Both statements are standard formulation science, not sermorelin results. The relevance of the freeze-dried state itself is implicit in the analytical papers, which relied on well-characterised reference standards; the 2023 study explicitly generated in-house standards from doping peptides and profiled their degradation (PMID 37688464). The number of freeze–thaw cycles a sermorelin solution can tolerate has not been established in the literature reviewed here.

Signs of Degradation: What Studies Report

Researchers did not rely on visual inspection to judge peptide integrity. In every verified method paper, identity and quantity were established instrumentally: nano liquid chromatography with quadrupole/orbitrap mass spectrometry for GHRH and its analogs in urine (PMID 41138283), nanoLC-HRMS/MS after ultrafiltration for urine at low pg/mL concentrations (PMID 35298973), and immunoaffinity-purified LC-HRMS/MS for plasma identification (PMID 26879649). Degradation itself was characterised as a profile of breakdown products in the 2023 stability study rather than as a colour or a cloudiness (PMID 37688464).

The implication reported across that body of work is that chemical loss in a peptide preparation is detected by assay, not by appearance. Visual cues sometimes cited in consumer discussions — discolouration, particulates, a cake that has collapsed or shifted — are quality-control heuristics from general pharmacy practice, and none of them was validated as a sermorelin degradation marker in these papers.

Limits of the evidence

Three limits are worth stating plainly. First, the sermorelin-adjacent stability data that exist were collected in serum and enzymatic systems for anti-doping standard development, not in storage-condition experiments (PMID 37688464). Second, the stabilisation literature for this peptide family is about molecular engineering, such as the PEGylation approaches reviewed for GRF analogues, not about handling practice (PMID 14499707). Third, much of the material in circulation sits outside pharmaceutical quality systems, a problem the 2026 sports-medicine review addressed directly in its critical assessment of peptide and peptide-analog drug use (PMID 41880199). Storage questions about a specific product are matters for the product's own documentation and for a licensed physician or pharmacist.

References

• In-house standards derived from doping peptides: Enzymatic and serum stability and degradation profile of GHRP and GHRH-related peptides (Biomedical Chromatography, 2023)
• PEGylation of growth hormone-releasing hormone (GRF) analogues (Advanced Drug Delivery Reviews, 2003)
• An antibody-free, ultrafiltration-based assay for the detection of growth hormone-releasing hormones in urine at low pg/mL concentrations using nanoLC-HRMS/MS (Journal of Pharmaceutical and Biomedical Analysis, 2022)
• Analysis of growth hormone releasing hormone and its analogs in urine using nano liquid chromatography coupled with quadrupole/orbitrap mass spectrometry (Journal of Pharmaceutical and Biomedical Analysis, 2026)
• Cationic exchange SPE combined with triple quadrupole UHPLC-MS/MS for detection of GHRHs in urine samples (Analytical Biochemistry, 2023)
• Qualitative identification of growth hormone-releasing hormones in human plasma by means of immunoaffinity purification and LC-HRMS/MS (Analytical and Bioanalytical Chemistry, 2016)
• A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review (The Journal of Sports Medicine and Physical Fitness, 2026)